Accessibility Menu
Arbutus Biopharma logo

Arbutus Biopharma(NASDAQ) ABUS

Market Cap$865.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-38%
5 Year+59%
1 Year+35%
1 Month-2%
$4.43
+1.03%
+0.04Today
Arbutus Biopharma last closing stock price
MetricPriceDate
Last closeUSD 4.382026-07-24
Arbutus Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.95%USD 4.562026-07-17
1 month-1.79%USD 4.462026-06-24
3 month+4.29%USD 4.202026-04-24
Year to date-8.94%USD 4.812025-12-31
1 year+35.19%USD 3.242025-07-24
3 year+105.63%USD 2.132023-07-25
5 year+58.7%USD 2.762021-07-23
Since inception-37.78%USD 7.042010-11-15

Arbutus Biopharma Financials at a Glance

Market Cap

$865.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$191.45M

Net Income (TTM)

$160.72M

EPS (TTM)

$0.82

P/E Ratio

5.33

Dividend

$0.00

Beta (Volatility)

0.97 (Low)

Price

$4.43

Volume

17,281

Open

$4.48

Previous Close

$4.43

Daily Range

$4.41 - $4.51

52-Week Range

$3.25 - $5.38

Estimated Earnings Date

Aug 5, 2026

ABUS News

Foolcom-Featured.png

Arbutus (ABUS) Q2 Revenue Surges 529%

Motley Fool Markets TeamAug 6, 2025
FDA blocks in hand

Why Arbutus Biopharma Stock Is Sinking Today

Keith SpeightsApr 25, 2023
Scientists in a lab

What's the Outlook for Arbutus Biopharma?

Keith SpeightsFeb 5, 2022
smart-investor-buying-stocks-getty

Why Arbutus Biopharma Is Rocketing Higher Today

Cory RenauerDec 1, 2021
Money Pills

Here's Why Arbutus Biopharma Fell Today

Brian Orelli, PhDAug 7, 2020
3-test-tubes-getty

3 Healthcare Stocks That Rocketed Higher in July

Cory RenauerAug 3, 2020
GettyImages-808705182

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

Taylor CarmichaelJul 24, 2020
Flask and lab background

Here's Why Arbutus Biopharma Corp. Is Tanking Today

Keith SpeightsOct 9, 2018
Page 1

ABUS: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arbutus Biopharma

Arbutus develops medicines for people with long-term liver infections. These treatments help the body's natural defenses fight the Hepatitis B virus. The company also creates systems that carry medicine safely into human cells.

Fighting Viruses and Delivering DNA

  • Imdusiran (AB-729): Injectable treatment that stops the Hepatitis B virus from making proteins; uses RNA interference (RNAi) to silence viral genes.
  • AB-101: Oral pill that helps the immune system find and attack virus-infected cells; works by blocking the PD-L1 protein.
  • LNP Technology: Delivery system using tiny fat-like particles called lipid nanoparticles to protect and transport medicine inside the body.
  • Royalty Interests: Rights to receive payments from sales of ONPATTRO, a medicine currently sold by Alnylam Pharmaceuticals.

Partners, Patents, and Legal Wins

  • In March 2026, Arbutus and Genevant settled a patent lawsuit with Moderna for an initial $950 million payment.
  • The company filed a patent lawsuit against Pfizer and BioNTech in April 2023 regarding its vaccine delivery technology.
  • In June 2025, Arbutus and Qilu Pharmaceutical ended their partnership, returning full global rights for imdusiran to Arbutus.
  • The company appointed a new executive team and five new board members in early 2025 to lead its clinical strategy.
  • Arbutus reduced its workforce by 57% in early 2025 and shifted to a remote work model to lower costs.

Why the Technology Matters

Arbutus holds key patents for lipid nanoparticles, which are essential for delivering genetic medicines into human cells. Its research combines gene-silencing tools with immune-boosting drugs to target a functional cure for chronic Hepatitis B.

Measuring Financial Progress

  • Revenue was $1.1 million in Q4 2025, down 33.2% from $1.6 million in Q4 2024.
  • Net loss reached $3.8 million in Q4 2025, narrowing from a $12.5 million loss in Q4 2024.
  • Free cash flow hit -$4.7 million in Q4 2025, which narrowed from a -$10.4 million outflow in Q4 2024.
  • Market capitalization reached $921.6 million in Q4 2025, up 51.8% from $606.9 million the previous year.

Bottom Line

Arbutus has evolved from a research-heavy firm to a clinical-stage developer focused on its Hepatitis B pipeline. Its strategy relies on protecting its delivery technology and advancing key treatments through human trials.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

19

CEO

Lindsay Androski, CFA, MBA

Website

www.arbutusbio.com

Headquarters

Warminster, PA 18974, US

ABUS Financials

Key Financial Metrics (TTM)

Gross Margin

99.98%

Operating Margin

80.79%

Net Income Margin

83.95%

Return on Equity

129.32%

Return on Capital

-33.49%

Return on Assets

57.99%

Earnings Yield

18.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$865.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

197.54M

Volume

17.28K

Avg. Volume

2.01M

Financials (TTM)

Gross Profit

$191.41M

Operating Income

$154.67M

EBITDA

$160.85M

Operating Cash Flow

-$34.36M

Capital Expenditure

$0.00

Free Cash Flow

-$34.36M

Cash & ST Invst.

$95.23M

Total Debt

$3.91M

Arbutus Biopharma Performance Analysis

Arbutus Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 39,019,000255.1%
20232023-12-31USD 18,141,000-53.5%
20242024-12-31USD 6,171,000-66.0%
20252025-12-31USD 14,083,000128.2%
Arbutus Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30508.8%
Q32025-09-30-95.1%
Q42025-12-3198.7%
Q12026-03-3116943.4%
Arbutus Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.46-44.7%
20232023-12-31USD -0.44-4.6%
20242024-12-31USD -0.38-14.2%
20252025-12-31USD -0.17-53.6%
Arbutus Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30110.1%
Q32025-09-30-405.3%
Q42025-12-3151.2%
Q12026-03-314561.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$179.13M

+10054.5%

Gross Profit

$179.12M

+2589.4%

Gross Margin

99.99%

N/A

Market Cap

$865.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$45.54M

N/A

Employees

19

N/A

Net Income

$169.70M

+791.9%

EBITDA

$169.72M

+802.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$95.23M

-15.5%

Total Debt

$3.91M

-30.2%

Accounts Receivable

$1.31M

+11.0%

Inventory

$0.00

N/A

Long Term Debt

$3.28M

-34.9%

Short Term Debt

$631.00K

+12.1%

Return on Assets

57.99%

N/A

Return on Invested Capital

56.85%

N/A

Free Cash Flow

-$8.11M

+39.4%

Operating Cash Flow

-$8.11M

+39.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KURAKura Oncology, Inc.
$10.15-2.31%
EYPTEyePoint Pharmaceuticals, Inc.
$12.41+1.80%
SVRASavara Inc.
$5.43-1.45%
SPRYARS Pharmaceuticals, Inc.
$5.76-3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About ABUS

What is the current price of Arbutus Biopharma?

Arbutus Biopharma is trading at $4.43 per share.

What is the 52-week range for Arbutus Biopharma?

Over the past 52 weeks, Arbutus Biopharma has traded between $3.25 and $5.38.

How much debt does Arbutus Biopharma have?

As of the most recent reporting period, Arbutus Biopharma reported total debt of $3.91M.

How much cash does Arbutus Biopharma have on hand?

Arbutus Biopharma reported $23.71M in cash and cash equivalents in its most recent financial results.

What is Arbutus Biopharma’s dividend yield?

Arbutus Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services